LEADER 01083cam0-2200361---450- 001 990004087100403321 005 20081201124713.0 035 $a000408710 035 $aFED01000408710 035 $a(Aleph)000408710FED01 035 $a000408710 100 $a19990604g19839999km-y0itay50------ba 101 0 $afre 102 $aCH 105 $ay---a---001yy 200 1 $a<>siècle des lumières$ebibliographie chronologique$fPierre M. Conlon 210 $aGenève$cDroz$d1983- 215 $av.$d23 cm 225 1 $aHistoire des idées et critique littéraire$v213 327 0 $a1.: 1716-1722. - 1983$a4.: 1737-1742 610 0 $aIlluminismo$aLetteratura$aBibliografia 610 0 $aIlluminismo francese$aSec.18.$aBibliografia 676 $a015.44 700 1$aConlon,$bPierre M.$0158203 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990004087100403321 952 $aSE 016.08.09-$b11$fDECSE 952 $a015.44 CON 1(1)$bDip.f.m.591$fFLFBC 959 $aFLFBC 959 $aDECSE 996 $aSiècle des lumières$9249423 997 $aUNINA LEADER 00939nam a2200265 i 4500 001 991003131309707536 005 20021205125928.0 008 021126s1993 sp ||| | spa 020 $a8475173934 035 $ab1175901x-39ule_inst 035 $aLE01283265$9ExL 040 $aDip.to Lingue$bita 100 1 $aMartin Gaite, Carmen$0132681 245 10$aDespues de todo :$bpoesia a rachas /$cCarmen Martin Gaite 250 $a4 ed., corregida y aumentada, presentada por Jesus Munarriz 260 $aMadrid :$bHiperion, $cc1993 300 $a114 p. ;$c20 cm. 490 0 $aPoesia Hiperion ;$v212 700 1 $aMunarriz, Jesus 907 $a.b1175901x$b27-04-17$c05-12-02 912 $a991003131309707536 945 $aLE012 868.64 MAT 9$g1$i2012000035034$lle012$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i12004054$z05-12-02 996 $aDespues de todo$9904779 997 $aUNISALENTO 998 $ale012$b01-01-02$cm$da $e-$fspa$gsp $h0$i1 LEADER 01698nam 2200349 450 001 9910688456203321 005 20230630044620.0 035 $a(CKB)5400000000044771 035 $a(NjHacI)995400000000044771 035 $a(EXLCZ)995400000000044771 100 $a20230630d2021 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances in Precision Medicine Oncology /$fHilal Arnouk, Bassam Hassan, editor 210 1$aLondon :$cIntechOpen,$d2021. 215 $a1 online resource (260 pages) 311 $a1-83968-869-6 330 $aRecent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. 606 $aCancer$xTreatment 615 0$aCancer$xTreatment. 676 $a616.99406 702 $aHassan$b Bassam 702 $aArnouk$b Hilal 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910688456203321 996 $aAdvances in Precision Medicine Oncology$92828415 997 $aUNINA